Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Elizabeth Fox et al.|The Lancet Oncology|2019Cited by 341
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Julie R. Park et al.|Nature Medicine|2023Cited by 125
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancerAlanna J. Church, Katherine A. Janeway, Laura Corson et al.|Nature Medicine|2022Cited by 65
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyRochelle Bagatell, Lisa Hang, Julie R. Park et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 47
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin Lerman, Rochelle Bagatell, Yimei Li et al.|Journal of Clinical Oncology|2022Cited by 42